DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost CAR-T safety in lymphoma patients
Disease control Recruiting nowThis early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before CAR-T cell therapy is safe and doable for people with large B-cell lymphoma. About 14 adults whose lymphoma has not responded or has come back will receive this combination. The goa…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control Recruiting nowThis trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New antibody combo aims to outperform standard lymphoma treatment
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called odronextamab, given together with standard chemotherapy (CHOP), for people with diffuse large B-cell lymphoma who have not been treated before or whose cancer has come back. The study compares this new combination to the curren…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill takes on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for older lymphoma patients: gentler, smarter treatment on the horizon?
Disease control Recruiting nowThis study is testing a new treatment for older adults (65 and up) with diffuse large B-cell lymphoma (DLBCL) or similar aggressive lymphomas. The treatment combines a targeted immunotherapy drug called glofitamab with standard chemotherapy, aiming to improve cancer remission whi…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo targets tough lymphoma subtypes in early trial
Disease control Recruiting nowThis study tests a new combination of drugs for people with a specific type of untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if the treatment can keep the cancer from coming back for at least two years. About 35 participants will receive six cycles of the dr…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New CAR-T study aims to boost cancer treatment success
Disease control Recruiting nowThis study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track how the modified immune cells grow and last in the body after infusion. The goal is to see if this treatment is effective in real-world s…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Smart scans and DNA tests could tailor lymphoma therapy, reducing chemo for some
Disease control Recruiting nowThis study tests a new way to treat diffuse large B-cell lymphoma (DLBCL) by using PET scans and blood DNA tests early in treatment to decide the best next steps. About 40 adults with untreated DLBCL will start standard chemo, then get either shorter chemo if tests show low risk,…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Last-Resort cancer therapy made available to patients with no other options
Disease control AVAILABLEThis program provides early access to CTL019, a cell therapy that reprograms a patient's own immune cells to attack cancer. It is for people with lymphoma or leukemia who have no other treatment choices and cannot join a clinical trial. The goal is to offer a potential benefit wh…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail of drugs shows promise for deadly brain cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs—pomalidomide, tislelizumab, and selinexor—in 43 people with relapsed or refractory primary central nervous system lymphoma. The goal is to see if this cocktail can shrink tumors and improve survival. All participants receive t…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New injection shows promise for tough lymphoma cases
Disease control Recruiting nowThis early-phase study tests a new drug called KSV01 in 18 adults with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has not responded to standard treatments. The main goal is to check the safety of the injection and find the best dose. Partici…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for aggressive lymphoma: precision therapy trial launches
Disease control Recruiting nowThis phase 2 trial is testing a combination of targeted drugs and chemotherapy in 35 people newly diagnosed with a specific, hard-to-treat form of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this precision approach can improve how long pa…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug could keep lymphoma at bay in hepatitis b patients
Disease control Recruiting nowThis Phase 3 trial is testing whether the drug chidamide can help prevent diffuse large B-cell lymphoma from returning in patients who also have hepatitis B. Participants must have achieved complete remission after initial chemotherapy (R-CHOP). They will take chidamide twice a w…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for elderly lymphoma patients: targeted combo aims to control aggressive cancer
Disease control Recruiting nowThis study tests a new drug combination for people aged 70 and older with a fast-growing type of lymphoma called double-expressor DLBCL. Participants receive chidamide pills plus a reduced-strength chemotherapy regimen, followed by maintenance therapy with chidamide and a targete…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called TC011, which uses a patient's own immune cells engineered to find and attack lymphoma cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial will check safety and h…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Last-Resort cancer drug made available to patients before approval
Disease control AVAILABLEThis program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have ex…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for elderly lymphoma patients: drug combo shows promise in early trial
Disease control Recruiting nowThis study tests a new combination of three drugs (chidamide, rituximab, and polatuzumab vedotin) in elderly patients with a specific type of untreated lymphoma called double-positive DLBCL. The goal is to see how many patients achieve complete remission after treatment. About 58…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail aims to beat tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who have high-risk features. About 50 participants will receive the combination…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Last-Resort drug made available for lymphoma patients
Disease control AVAILABLEThis program provides compassionate use of odronextamab for people with relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, or other B-cell non-Hodgkin lymphomas who have no other treatment options. Odronextamab is a drug that helps the immune system attack…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat brain cancer
Disease control Recruiting nowThis pilot study is testing a new treatment called Anbal-cel for people with relapsed or refractory primary or secondary central nervous system lymphoma. Anbal-cel is a CAR-T cell therapy made from the patient's own immune cells. The study will enroll 12 participants to see if th…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill takes on aggressive lymphoma in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called rocbrutinib alone against standard treatments for a specific, aggressive type of lymphoma (non-GCB DLBCL) that has returned or not responded to prior therapy. About 150 adults will be randomly assigned to receive either rocbrutinib or a standard…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New strategy targets lingering lymphoma DNA in seniors
Disease control Recruiting nowThis study is for people aged 70 and older with a type of blood cancer called DLBCL. After initial chemotherapy, a blood test checks for leftover cancer DNA. If found, patients receive an extra targeted drug (mosunetuzumab) to try to clear it. The goal is to improve disease contr…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
Lifestyle plan aims to boost Well-Being in lymphoma survivors
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Herbal capsule tested to fight chemo exhaustion in blood cancer survivors
Symptom relief Recruiting nowThis study tests whether Xinlikang capsules can reduce severe fatigue and improve immune health in people with diffuse large B-cell lymphoma who have finished chemotherapy and are in remission. About 80 participants will receive either the capsule or a placebo. The goal is to see…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Rare lymphoma transformation under study: what happens when aggressive cancer comes back mild?
Knowledge-focused Recruiting nowThis study looks at a rare event where an aggressive lymphoma (DLBCL) comes back as a slow-growing (indolent) lymphoma. Researchers will review medical records of 50 adults to understand how often this happens, what treatments are used, and how well patients do. The goal is to ga…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive german study to track how blood cancer patients really fare
Knowledge-focused Recruiting nowThis study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC